Category: Uncategorized

A new study published in the Journal of the American Academy of Dermatology (JAAD) shows that COVID-19 has materially delayed diagnosis for patients with skin cancer and a substantial backlog of undiagnosed cases remain. Rates of skin cancer detection in the study were down by 43-51%. These delays in initial diagnosis and treatment may lead to skin cancers presenting at more advanced stages, with potential increased morbidity and worse melanoma survival outcomes.

The study was based on data collected by the Advanced Dermatology and Cosmetic Surgery (ADCS) group of practices in the US. ADCS is a key partner for SciBase in the US, though SciBase was not directly involved in the study.

"This study shows that COVID-19 has had a significant negative effect on the rates of skin cancer diagnosis, primarily due to a reluctance from patients to visit clinics. This effect has been seen in Europe as well. We expect an increased focus on skin cancer and diagnosis once effects of the pandemic have subsided, and this represents a likely increase in demand for products such as ours", says Simon Grant, CEO of SciBase.

The article can be accessed through the following link: https://www.jaad.org/article/S0190-9622%2821%2900082-7/fulltext

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se  

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

A new study published in the Journal of the American Academy of Dermatology (JAAD) shows that COVID-19 has materially delayed diagnosis for patients with skin cancer and a substantial backlog of undiagnosed cases remain. Rates of skin cancer detection in the study were down by 43-51%. These delays in initial diagnosis and treatment may lead to skin cancers presenting at more advanced stages, with potential increased morbidity and worse melanoma survival outcomes.

The study was based on data collected by the Advanced Dermatology and Cosmetic Surgery (ADCS) group of practices in the US. ADCS is a key partner for SciBase in the US, though SciBase was not directly involved in the study.

"This study shows that COVID-19 has had a significant negative effect on the rates of skin cancer diagnosis, primarily due to a reluctance from patients to visit clinics. This effect has been seen in Europe as well. We expect an increased focus on skin cancer and diagnosis once effects of the pandemic have subsided, and this represents a likely increase in demand for products such as ours", says Simon Grant, CEO of SciBase.

The article can be accessed through the following link: https://www.jaad.org/article/S0190-9622%2821%2900082-7/fulltext

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se  

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

A new study published in the Journal of the American Academy of Dermatology (JAAD) shows that COVID-19 has materially delayed diagnosis for patients with skin cancer and a substantial backlog of undiagnosed cases remain. Rates of skin cancer detection in the study were down by 43-51%. These delays in initial diagnosis and treatment may lead to skin cancers presenting at more advanced stages, with potential increased morbidity and worse melanoma survival outcomes.

The study was based on data collected by the Advanced Dermatology and Cosmetic Surgery (ADCS) group of practices in the US. ADCS is a key partner for SciBase in the US, though SciBase was not directly involved in the study.

"This study shows that COVID-19 has had a significant negative effect on the rates of skin cancer diagnosis, primarily due to a reluctance from patients to visit clinics. This effect has been seen in Europe as well. We expect an increased focus on skin cancer and diagnosis once effects of the pandemic have subsided, and this represents a likely increase in demand for products such as ours", says Simon Grant, CEO of SciBase.

The article can be accessed through the following link: https://www.jaad.org/article/S0190-9622%2821%2900082-7/fulltext

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se  

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

A new clinical study evaluating the value of using Nevisense on suspected Non-melanoma skin cancer (also known as Keratinocyte cancer) in normal clinical practice is now published. The article named "Retrospective evaluation of the performance of the electrical impedance spectroscopy system Nevisense in detecting keratinocyte cancer" reviewed clinical results when Nevisense was used on lesions with a suspicion of skin cancer.

The study included a total of 1,712 lesions and 951 patients, collected at a private clinic in Germany over a period of 4 years. The study confirmed the ability of Nevisense to accurately identify non-melanoma skin cancers with a sensitivity of 98,4%. In addition, the study showed that when using Nevisense almost half of the lesions examined did not require a biopsy. The article concludes that Nevisense is a valuable adjunct support tool in clinical decisions for cases with suspicion of non-melanoma skin cancer. The article is available through the following link: http://dx.doi.org/10.1111/srt.13007 

These results support a new clinical application that is an important part of our growth strategy. We continue to leverage our technology platform to both add clinical value and expand the market segments we address. We believe that the Non-melanoma Skin Cancer application will help us achieve both goals, and short term be key in accelerating our growth in Germany. We look forward to releasing the application as soon as our Medical Device Regulation approval is complete, which we expect around the end of the first quarter", says Simon Grant, CEO of SciBase.

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se  

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

A new clinical study evaluating the value of using Nevisense on suspected Non-melanoma skin cancer (also known as Keratinocyte cancer) in normal clinical practice is now published. The article named "Retrospective evaluation of the performance of the electrical impedance spectroscopy system Nevisense in detecting keratinocyte cancer" reviewed clinical results when Nevisense was used on lesions with a suspicion of skin cancer.

The study included a total of 1,712 lesions and 951 patients, collected at a private clinic in Germany over a period of 4 years. The study confirmed the ability of Nevisense to accurately identify non-melanoma skin cancers with a sensitivity of 98,4%. In addition, the study showed that when using Nevisense almost half of the lesions examined did not require a biopsy. The article concludes that Nevisense is a valuable adjunct support tool in clinical decisions for cases with suspicion of non-melanoma skin cancer. The article is available through the following link: http://dx.doi.org/10.1111/srt.13007 

These results support a new clinical application that is an important part of our growth strategy. We continue to leverage our technology platform to both add clinical value and expand the market segments we address. We believe that the Non-melanoma Skin Cancer application will help us achieve both goals, and short term be key in accelerating our growth in Germany. We look forward to releasing the application as soon as our Medical Device Regulation approval is complete, which we expect around the end of the first quarter", says Simon Grant, CEO of SciBase.

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se  

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

A new clinical study evaluating the value of using Nevisense on suspected Non-melanoma skin cancer (also known as Keratinocyte cancer) in normal clinical practice is now published. The article named "Retrospective evaluation of the performance of the electrical impedance spectroscopy system Nevisense in detecting keratinocyte cancer" reviewed clinical results when Nevisense was used on lesions with a suspicion of skin cancer.

The study included a total of 1,712 lesions and 951 patients, collected at a private clinic in Germany over a period of 4 years. The study confirmed the ability of Nevisense to accurately identify non-melanoma skin cancers with a sensitivity of 98,4%. In addition, the study showed that when using Nevisense almost half of the lesions examined did not require a biopsy. The article concludes that Nevisense is a valuable adjunct support tool in clinical decisions for cases with suspicion of non-melanoma skin cancer. The article is available through the following link: http://dx.doi.org/10.1111/srt.13007 

These results support a new clinical application that is an important part of our growth strategy. We continue to leverage our technology platform to both add clinical value and expand the market segments we address. We believe that the Non-melanoma Skin Cancer application will help us achieve both goals, and short term be key in accelerating our growth in Germany. We look forward to releasing the application as soon as our Medical Device Regulation approval is complete, which we expect around the end of the first quarter", says Simon Grant, CEO of SciBase.

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se  

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

Christer Jönsson (Fouriertransform),

Iraj Arastoupour (Futur pension),

Peter Elmvik,

Tord Lendau (Chairman of the Board).

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 17, 2020. Note, however, that the appointment took into account changes in ownership that took place during the end of 2020.

The Annual General Meeting of SciBase Holding AB (publ) will be held on May 18, 2021 in Stockholm.

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Stockholm, February 2, 2021

SciBase Holding AB (publ) 

For more information, please contact:
Tord Lendau, Chairmain of the board, phone +46 (0)70 810 01 67

Michael Colérus, CFO, phone +46 70 341 34 72

Certified Advisor (CA):

Avanza

Tel: +46 8 409 421 20

Email: ca@avanza.se

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

Christer Jönsson (Fouriertransform),

Iraj Arastoupour (Futur pension),

Peter Elmvik,

Tord Lendau (Chairman of the Board).

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 17, 2020. Note, however, that the appointment took into account changes in ownership that took place during the end of 2020.

The Annual General Meeting of SciBase Holding AB (publ) will be held on May 18, 2021 in Stockholm.

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Stockholm, February 2, 2021

SciBase Holding AB (publ) 

For more information, please contact:
Tord Lendau, Chairmain of the board, phone +46 (0)70 810 01 67

Michael Colérus, CFO, phone +46 70 341 34 72

Certified Advisor (CA):

Avanza

Tel: +46 8 409 421 20

Email: ca@avanza.se

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

• New clinical study supports expansion of indications for Nevisense 
• Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer 
• The study publication is an important milestone in the plan to broaden the areas of use of Nevisense

A new study supporting the use of Nevisense for the evaluation of lesions where there is a suspicion of non-melanoma skin cancer (NMSC) has been published in "Acta Dermato-Venereologica". The article is authored by Dr Esra Sarac, Prof Claus Garbe and others from Eberhard Karls University in Tübingen, Germany. NMSC represents a new indication that complements the current melanoma indication and greatly expands the utility of Nevisense for clinicians working with skin cancer.

"This study shows that Nevisense is a valuable tool not only for melanoma but also for other types of skin cancer such as basal cell carcinoma and squamous cell carcinoma. These non-melanoma skin cancers are 10-15 times more prevalent than melanoma, and so the new indication will be more useful to more clinicians and patients. The publication is another milestone in our strategy to broaden the clinical applications and markets for Nevisense. Nevisense with NMSC is now in the final stages of regulatory approval in the EU as part of the new Medical Device Regulation approval route. Once approved, we expect the added indication will make Nevisense more attractive for new customers and expand the level of usage of existing customers", says Simon Grant, CEO of SciBase.

The article is titled "Diagnostic Accuracy of Electrical Impedance Spectroscopy in Nonmelanoma Skin Cancer" and evaluates the accuracy of Nevisense and Electrical Impedance spectroscopy (EIS) on suspected non-melanoma skin cancers. The article shows that Nevisense is well suited for use with NMSC and states that "EIS has good discriminative power to distinguish NMSC from benign cutaneous lesions". The conclusion in the article states: "The results of this study suggest that electrical impedance spectroscopy measurements can improve diagnostic performance with a high sensitivity in detection of non-melanoma skin cancer."

The article is now available in online form at the Acta Dermato-Venereologica's website (https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3689) and will be distributed in print in the next issue of the publication. 

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com  

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se   

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

• New clinical study supports expansion of indications for Nevisense 
• Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer 
• The study publication is an important milestone in the plan to broaden the areas of use of Nevisense

A new study supporting the use of Nevisense for the evaluation of lesions where there is a suspicion of non-melanoma skin cancer (NMSC) has been published in "Acta Dermato-Venereologica". The article is authored by Dr Esra Sarac, Prof Claus Garbe and others from Eberhard Karls University in Tübingen, Germany. NMSC represents a new indication that complements the current melanoma indication and greatly expands the utility of Nevisense for clinicians working with skin cancer.

"This study shows that Nevisense is a valuable tool not only for melanoma but also for other types of skin cancer such as basal cell carcinoma and squamous cell carcinoma. These non-melanoma skin cancers are 10-15 times more prevalent than melanoma, and so the new indication will be more useful to more clinicians and patients. The publication is another milestone in our strategy to broaden the clinical applications and markets for Nevisense. Nevisense with NMSC is now in the final stages of regulatory approval in the EU as part of the new Medical Device Regulation approval route. Once approved, we expect the added indication will make Nevisense more attractive for new customers and expand the level of usage of existing customers", says Simon Grant, CEO of SciBase.

The article is titled "Diagnostic Accuracy of Electrical Impedance Spectroscopy in Nonmelanoma Skin Cancer" and evaluates the accuracy of Nevisense and Electrical Impedance spectroscopy (EIS) on suspected non-melanoma skin cancers. The article shows that Nevisense is well suited for use with NMSC and states that "EIS has good discriminative power to distinguish NMSC from benign cutaneous lesions". The conclusion in the article states: "The results of this study suggest that electrical impedance spectroscopy measurements can improve diagnostic performance with a high sensitivity in detection of non-melanoma skin cancer."

The article is now available in online form at the Acta Dermato-Venereologica's website (https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3689) and will be distributed in print in the next issue of the publication. 

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com  

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se   

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.